Moderna continues to reshape its pipeline, purging three more projects, and announcing a three-year plan backed by a $1.5 billion loan. The biotechnology firm extends its footprint in U.S manufacturing through a $140M plant pushing for end-to-end mRNA production. The expansion, amid controversies, tuples the Norwood, MA site for mRNA manufacturing. Research indicates mRNA COVID vaccines may assist certain cancer patients to fight tumors. However, Moderna's mRNA vaccines get canned, as the firm secures a loan envisioning a 10% growth. Intrigue ensues concerning Moderna's valuation, fostered by investor sentiment with Royal Bank Of Canada and Leerink Partners' forecasts. Moderna's Q3 report shows a loss but impressive revenue. Future growth is targeted through strategic innovations, despite a significant share price drop following the 2025 sales outlook cut and cessation of the CMV vaccine program. The firm eyes therapeutic trials, focusing on cancer vaccines. Amidst setbacks, Moderna projects growth with promising flu vaccine trial data and multiple investments underpinning expansion strategies. Yet, Moderna scraps the mRNA vaccine for congenital CMV after Phase III failure. Some consider RFK Jr.'s decision to cease mRNA vaccine support a loss for Moderna, despite recent FDA approval for next-generation COVID-19 vaccine.
Moderna MRNA News Analytics from Sat, 24 May 2025 07:00:00 GMT to Sat, 22 Nov 2025 14:59:49 GMT -
Rating 4
- Innovation 5
- Information 8
- Rumor -2
